Truist Securities Reiterates Buy on Elevance Health, Lowers Price Target to $520
Portfolio Pulse from Benzinga Newsdesk
Truist Securities has reiterated its Buy rating on Elevance Health but has lowered the price target from $620 to $520.

October 18, 2024 | 1:35 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
Truist Securities has reiterated its Buy rating on Elevance Health, indicating continued confidence in the stock. However, the price target has been lowered from $620 to $520, suggesting a more conservative outlook on its potential upside.
The reiteration of the Buy rating suggests that the analyst still sees value in Elevance Health, but the lowered price target indicates a tempered expectation for its future performance. This mixed signal may result in a neutral short-term impact on the stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100